Taken together, these results point to a potential role of PARP inhibitors in the treatment of LC patients, particularly in those with underlying respiratory conditions as tumors of those without COPD did not experience an increase in PARP activity. The gene discussed is PARP1; the disease is laryngotracheoesophageal cleft.